Japanese Levaltinib, LENVIMA
Common name: Levatinib
Drug name: LENVIMA
English name: LENVIMA
Chinese Pinyin name: Lefatini
Main Ingredients: Lenvatinib Methanesulfonate
Pharmaceutical traits Mesylate is a white powder with a pale reddish yellow color.
Usage and Dosage
1) Recommended dose: 24mg orally, once a day.
2) In patients with severe kidney or liver damage, the dose is 14 mg once daily.
For the treatment of unresectable, locally advanced or metastatic symptomatic or progressive medullary thyroid cancer.
1) Hypertension: Control blood pressure before treatment with LENVIMA. LENVIMA is not given to grade 3 hypertension despite optimal hypertension treatment. Terminating drugs for life-threatening hypertension.
2) Heart Failure: Monitor clinical signs and symptoms of cardiac decompensation. Do not give LENVIMA heart dysfunction to level 3. Termination of drugs for grade 4 cardiac insufficiency.
3) Arterial thromboembolic events: LENVIMA is terminated after an arterial thromboembolic event.
4) Hepatotoxicity: Liver function tests are monitored regularly before and during LENVIMA. LENVIMA is not given for grade 3 or greater liver damage. Termination of treatment for liver failure (5.4).
5) Proteinuria: Monitor proteinuria before starting treatment with LENVIMA and periodically from start to finish. For 24 hours urine protein ≥ 2 grams does not give LENVIMA. Termination of medication for nephrotic syndrome.
6) Renal failure and kidney damage: LENVIMA is not given for grade 3 or 4 renal failure/damage.
7) Gastrointestinal perforation and fistula formation: termination of LENVIMA in patients with gastrointestinal perforation or life-threatening fistula.
8) QT interval prolongation: Monitor and correct electrolyte abnormalities in all patients. Do not give LENVIMA for QT interval extension of level 3 or greater
9) Hypocalcemia: Monitor blood calcium levels for at least monthly and as needed to give replacement calcium.
10) Reversible posterior leukoencephalopathy syndrome (RPLS): LENVIMA is not given to RPLS until complete resolution.
11) Bleeding event: LENVIMA is not given for grade 3 bleeding. Termination of treatment for grade 4 bleeding.
12) Impaired Thyroid Stimulating Hormone Inhibition: Monitors TSH levels on a monthly basis and adjusts thyroid replacement medication if needed in patients with DTCs.
13) Embryo fetal toxicity: may cause fetal harm. Advise on potential risks to the fetus and use effective contraception.
The most common adverse reactions to LENVIMA (incidence rate greater than or equal to 30%) are high blood pressure, fatigue, diarrhea, joint pain/muscle pain, loss of appetite, weight loss, nausea, stomatitis, headache, vomiting, proteinuria Pain, swollen red syndrome, abdominal pain, and dysphonia.
Pharmacological Toxicity Lenvatinib is a receptor tyrosine kinase (RTK) inhibitor that inhibits vascular endothelial growth factor kinase activity (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). Lenvatinib also inhibits other angiogenesis, tumor growth, and cancer progression that have been implicated in pathogenesis, in addition to its normal cellular function of other RTKs, including the fibroblast growth factor (FGF) receptors FGFR1, 2, 3, and 4; Platelet-derived growth factor receptor alpha (PDGFR alpha), KIT, and RET. Lenvatinib and combined everolimus demonstrated to demonstrate in vitro and tumor volume reduction in human kidney cell carcinoma in a larger mouse xenograft model than each drug alone, human endothelial cell proliferation, lumen formation, and increased VEGF signaling to anti-vascular Generation and anti-tumor activity.
There is no specific anti-toxicity to the excess of LENVIMA. Due to high plasma protein binding, lenvatinib is not expected to be dialyzed.
Adverse events in patients receiving a single dose of LENVIMA up to 40 mg were similar to those reported in the recommended dose clinical study.
Pregnant women and breast-feeding drugs Stop breastfeeding.
Store at 25 ° C (77 ° F); go out to 15 ~ 30 ° C (59 - 86 ° F).
Business Name Japan Eisai Pharmaceutical Co., Ltd.